Egis Pharmaceuticals PLC has acquired Sorbifer’s product rights from AstraZeneca. The transaction reinforces Egis’ position on its key markets. details >
The recognition, founded by the Minister of National Economy, is given the investors, SME-s and start-ups which have achieved outstanding results. In December 2016, Egis Pharmaceuticals was awarded “Investor of the month”. details >
Egis Pharmaceuticals today announced that it has generated $110 million (USD) in revenue related to the collaboration and sale of generic rosuvastatin calcium by Actavis in the United States. details >